BTK and graft versus host disease: Some of the new therapies are the use of post-transplant cyclophosphamide to diminish alloreactivity and decrease GvHD severity, Janus kinase inhibition and Bruton's tyrosine kinase inhibition for GvHD therapy, selective T-cell depletion and T-cell add back for diminishing GvHD and enhancing GvT.